AI tool to predict gene changes in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests an AI tool that looks at your tumor tissue images to predict certain gene changes (EGFR, ALK, ROS1) without needing extra tests. If you have non-small cell lung cancer and haven't had treatment yet, this could help guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer (a common type of lung cancer) that has spread or is at a late stage.
- You have tumor tissue samples (biopsies) that can be reviewed by the AI system.
- You have not had any prior cancer treatment like chemotherapy, radiation, or targeted therapy.
- You are willing to follow the study plan and give your consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses artificial intelligence to predict how well EGFR-targeted therapy will work for people with certain lung cancers. It looks at your imaging and genetic information to help guide treatment.
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
This study tests an artificial intelligence (AI) system that uses your health information and medical images to better judge cancer risk and support diagnosis and treatment decisions. It may help doctors make more consistent assessments by combining clinical records, imaging, and other lab-style data.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
Hear when a new Non Small Cell Lung Caner trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.